^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    VLS-211

    i
    Other names: VLS-211, UC-961/PNU payload, cirmtuzumab//PNU payload
    Company:
    Merck (MSD)
    Drug class:
    Topoisomerase II inhibitor, ROR1-targeted antibody-drug conjugate
    Related drugs:
    3years
    [VIRTUAL] Evaluation of ROR1-targeted antibody-drug conjugates against ROR1-expressing pediatric preclinical models - a report from the pediatric preclinical testing consortium (PPTC) (AACR 2021)
    UC-961 (cirmtuzumab), a humanized IgG1 monoclonal antibody, binds with high affinity to a specific extracellular epitope of human ROR1 and rapidly internalizes and traffics to lysosomes. VLS-101 and VLS-211 showed expression-level dependent activity against ALL and EWS models. These results support ROR1 as a relevant immuno-oncology target for the subset of B-ALL and Ewing sarcoma cases with elevated ROR1 expression. Further research is required to identify the optimal payload for ROR1 ADCs for use against pediatric cancers.
    Preclinical • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • ETV6 (ETS Variant Transcription Factor 6) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)
    |
    ROR1 expression
    |
    zilovertamab (UC-961) • zilovertamab vedotin (MK-2140) • VLS-211